Tuberculosis preventive chemotherapy: the times they are a-changin'

Affiliations

¹ Heart of England Foundation Trust, Birmingham, UK; University of Warwick, Coventry, UK.
² Division of Clinical Infectious Diseases, Research Center Borstel, Germany; German Center for Infection Research, Clinical Tuberculosis Center, Borstel, Germany; International Health / Infectious Diseases, University of Lübeck, Lübeck, Germany; Department of Medicine, Karolinska Institute, Stockholm, Sweden; Department of Internal Medicine, University of Namibia School of Medicine, Windhoek, Namibia.

Editorial

Martin Dedicoat et al. Int J Tuberc Lung Dis. 2015 Sep.

. 2015 Sep;19(9):1002.

doi: 10.5588/ijtld.15.0599.

¹ Heart of England Foundation Trust, Birmingham, UK; University of Warwick, Coventry, UK.
² Division of Clinical Infectious Diseases, Research Center Borstel, Germany; German Center for Infection Research, Clinical Tuberculosis Center, Borstel, Germany; International Health / Infectious Diseases, University of Lübeck, Lübeck, Germany; Department of Medicine, Karolinska Institute, Stockholm, Sweden; Department of Internal Medicine, University of Namibia School of Medicine, Windhoek, Namibia.

No abstract available

Comment on

Three months of weekly rifapentine plus isoniazid is less hepatotoxic than nine months of daily isoniazid for LTBI.
Bliven-Sizemore EE, Sterling TR, Shang N, Benator D, Schwartzman K, Reves R, Drobeniuc J, Bock N, Villarino ME; TB Trials Consortium. Bliven-Sizemore EE, et al. Int J Tuberc Lung Dis. 2015 Sep;19(9):1039-44, i-v. doi: 10.5588/ijtld.14.0829. Int J Tuberc Lung Dis. 2015. PMID: 26260821 Free PMC article. Clinical Trial.